Beat
Biotech & Longevity
Drug trials, gene editing, and longevity — the science with the caveats intact.
June 2026
Saturday, 13 June 2026
A cancer therapy just put five lupus patients into remission — and it points at a dozen more diseases
A one-time treatment built to kill blood cancer reset the immune systems of patients with severe lupus. The same tool is now being aimed at MS and rheumatoid arthritis.
Friday, 12 June 2026
The week antibiotic resistance got the AI treatment — and a warning that even the leftovers train the bugs
Researchers turned a suite of AI tools loose on the search for new antibiotics, while a separate study found that the breakdown products of old ones drive resistance nearly as hard as the drugs themselves. Plus a world-first cell-rejuvenation trial, a 1920s vaccine helping diabetes, and a drug to save muscle on weight-loss jabs.
Thursday, 11 June 2026
Scientists precisely edited human embryos for the first time — and the edit didn't stay put
A US-led team used base editing to correct disease mutations in human embryos with a precision standard CRISPR can't match. The same week showed how far the tool still is from a baby — and how fast the rest of the field is moving.
Wednesday, 10 June 2026
Ebola is winning in Congo — not because the science failed, but because the system around it did
One of the largest Ebola outbreaks ever is outrunning the response in eastern Congo, where medics improvise without boots or masks while donors scramble. The week's other science news was full of vaccines being built. The gap between the two is the whole story.
Tuesday, 9 June 2026
A startup with no human data just raised $435 million to reverse ageing
This week the biggest numbers in biotech went to the least proven ideas — a longevity company about to run its first-ever human trial pulled in $435M, while a company with an actual drug got stopped cold by the FDA. The gap between the two is the whole story.
Monday, 8 June 2026
The week's biggest medical news wasn't a drug — it was who's allowed to sell one
A unanimous Supreme Court ruling on generic drugs, and a fight over who gets to jump the FDA's queue, decided more about which medicines you can actually afford than any lab result did. The molecule is the easy half; the rules are the other half.
Sunday, 7 June 2026
A cancer drug that pulls off tumours' invisibility cloak — and the week the caveats mattered
At the world's biggest cancer meeting, an Oxford drug shrank tumours in patients who had run out of options. The same week showed why one good result is never the whole story.
Saturday, 6 June 2026
An AI-designed vaccine clears its first human trial
For the first time, a vaccine whose key component was designed by AI passed a first-in-human test — a real milestone, with real caveats — while big money bets on AI-designed drugs, an Ebola outbreak outruns the science, and longevity raises hundreds of millions before its first trial.
Friday, 5 June 2026
The new cancer drugs don't fight harder — they strip the disguise
At the world's largest cancer meeting, the standout results came from treatments that unmask tumours so the immune system can find them. Plus: weight-loss drugs keep showing benefits far beyond weight, gene therapy gets a regulatory tailwind, and an honest answer on how long humans can live — we don't know.
Thursday, 4 June 2026
Cancer survives by hiding — and this week's news is about making it visible again
At the big annual cancer meeting, the theme was the same trick from many angles: tumours stay alive by hiding from the immune system, so the new treatments strip the disguise or train the body to see through it. One study found the hiding itself can be a weakness. Plus a longevity startup raises $435 million before its first human trial, a masterclass in reading past a trial headline, and a lawsuit about why consent exists.
Wednesday, 3 June 2026
The weight-loss drugs keep doing things they weren't designed to do
Two large studies this week tie GLP-1 drugs to less cancer and less addiction — both are association, not proof. Plus real cancer-immunotherapy wins, a hepatitis B near-cure, and a longevity reality check.